Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Implication for practice and research
■ Combined oral contraceptives (OCs) increase the risk of venous thromboembolism (VTE).
■ The risk of VTE in users of OCs containing desogestrel, gestodene, cyproterone and drospirenone is around twice that of levonorgestrel OCs users.
■ Differences in VTE risk should be taken into consideration when prescribing OCs.
Oral contraceptives first introduced in the 1960s contained high doses of estrogen and progestin. These were associated with increased risk for cardiovascular disease (CVD), including VTE, and high estrogen dose was thought to be responsible.1 In subsequent years, OCs containing lower estrogen doses and different progestins …
Competing interests None.